United Therapeutics Co. (NASDAQ:UTHR)’s stock price reached a new 52-week high during trading on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $185.00 to $212.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. United Therapeutics traded as high as $200.17 and last traded at $199.83, with a volume of 12950 shares. The stock had previously closed at $191.10.
Other research analysts have also recently issued reports about the company. Wedbush lifted their price objective on United Therapeutics from $255.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday, February 25th. They noted that the move was a valuation call. Cowen upped their price target on shares of United Therapeutics from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 20th. Credit Suisse Group lifted their target price on shares of United Therapeutics from $169.00 to $196.00 and gave the company an “outperform” rating in a research note on Monday, March 1st. Oppenheimer upped their target price on shares of United Therapeutics from $200.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, February 16th. Finally, HC Wainwright raised United Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $125.00 to $195.00 in a report on Monday, February 1st. Eight analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $208.13.
In other United Therapeutics news, Director Judy D. Olian sold 4,207 shares of the firm’s stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $184.96, for a total transaction of $778,126.72. Following the completion of the transaction, the director now owns 9,997 shares in the company, valued at approximately $1,849,045.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Judy D. Olian sold 2,103 shares of United Therapeutics stock in a transaction that occurred on Wednesday, March 17th. The stock was sold at an average price of $170.00, for a total value of $357,510.00. Following the completion of the sale, the director now directly owns 7,893 shares in the company, valued at approximately $1,341,810. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in UTHR. Signaturefd LLC lifted its position in United Therapeutics by 54.0% during the fourth quarter. Signaturefd LLC now owns 308 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 108 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of United Therapeutics by 1.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 8,273 shares of the biotechnology company’s stock valued at $1,256,000 after acquiring an additional 125 shares during the last quarter. Federated Hermes Inc. grew its position in United Therapeutics by 0.8% in the fourth quarter. Federated Hermes Inc. now owns 19,602 shares of the biotechnology company’s stock worth $2,975,000 after acquiring an additional 148 shares in the last quarter. Parallel Advisors LLC increased its stake in United Therapeutics by 42.2% during the fourth quarter. Parallel Advisors LLC now owns 590 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 175 shares during the last quarter. Finally, Nicollet Investment Management Inc. raised its position in United Therapeutics by 3.6% during the fourth quarter. Nicollet Investment Management Inc. now owns 5,987 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 209 shares during the period. 90.09% of the stock is currently owned by institutional investors.
The firm has a market capitalization of $8.94 billion, a P/E ratio of 18.08 and a beta of 0.52. The company has a current ratio of 7.22, a quick ratio of 6.88 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average price of $170.31 and a 200-day moving average price of $147.53.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Tuesday, February 23rd. The biotechnology company reported $2.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.96 by ($0.77). United Therapeutics had a return on equity of 15.48% and a net margin of 33.25%. The company had revenue of $384.90 million during the quarter, compared to the consensus estimate of $362.04 million. During the same quarter in the prior year, the business earned $1.96 earnings per share. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Co. will post 12.55 earnings per share for the current year.
About United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.